Opinion

Video

Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy

Author(s):

Lauren Elman, MD,Arun S. Varadhachary, MD, PhD

Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.

  1. Discuss real-world evidence for risdiplam in adult patients.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!
Related Videos
Sylvia Villeneuve, PhD
1 expert in this video
Cheryl Kyinn, PA-C
Related Content
Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose
September 3rd 2025

Eisai Submits sBLA for Weekly Subcutaneous Lecanemab as Starting Dose

Marco Meglio
Clinical Insights on Dyskinesia and Tremor in Parkinson’s Disease
September 3rd 2025

Clinical Insights on Dyskinesia and Tremor in Parkinson’s Disease

Daniel E. Kremens, MD, JD Fernando Luis Pagan, MD Yasar Torres-Yaghi, MD
Real-World Data Points to Greater Impact of Semaglutide Over Tirzepatide in Reducing Heart Attack, Stroke Risk
September 3rd 2025

Real-World Data Points to Greater Impact of Semaglutide Over Tirzepatide in Reducing Heart Attack, Stroke Risk

Marco Meglio
Episode 148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care
September 3rd 2025

Episode 148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care

Marco Meglio Danielle Andrade, MD, MSc
Greater Sedentary Time Leads to Worse Cognition, Increased Neurodegeneration
September 3rd 2025

Greater Sedentary Time Leads to Worse Cognition, Increased Neurodegeneration

Marco Meglio
This Week on NeurologyLive® — September 1, 2025
September 3rd 2025

This Week on NeurologyLive® — September 1, 2025

Isabella Ciccone, MPH
© 2025 MJH Life Sciences

All rights reserved.